Detection of Malignant Primary Hepatic Neoplasms with Gadobenate Dimeglumine (Gd-BOPTA) Enhanced T1-Weighted Hepatocyte Phase MR Imaging: Results of Off-site Blinded Review in a Phase-II Multicenter Trial

Korean Journal of Radiology

Volumn 2, Issue 4, 2001, Pages 210-215

  Peña, Constantino S ^a   Saini, Sanjay ^a   Baron, Richard L ^b   Hamm, Bernd A ^c   Morana, Giovanni ^d   Caudana, Roberto ^d   Giovagnoni, Andrea ^e   Villa, Andrea ^f   Carriero, Alessandro ^g   Mathieu, Didier ^h   Bourne, Michael W ⁱ   Kirchin, Miles A ^j   Pirovano, Gianpaolo ^j   Spinazzi, Alberto ^j  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HUMBOLDT UNIVERSITY   (Germany)

^d POLICLINICO BORGO ROMA   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^g Oncology Unit   (Italy)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^j Bracco SpA   (Italy)

more..

Author keywords

Liver neoplasms, diagnosis; Liver neoplasms, MR; Magnetic resonance (MR), contrast media

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOBENIC ACID; MEGLUMINE; ORGANOMETALLIC COMPOUND;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; IMAGE ENHANCEMENT; LIVER ADENOMA; LIVER TUMOR; MALE; METHODOLOGY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL;

ADENOMA, LIVER CELL; ADULT; AGED; CONTRAST MEDIA; FEMALE; HUMAN; IMAGE ENHANCEMENT; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGE; ORGANOMETALLIC COMPOUNDS;

EID: 0035490482     PISSN: 12296929     EISSN: None     Source Type: Journal    
DOI: 10.3348/kjr.2001.2.4.210     Document Type: Article

References (20)

1. Miller WJ, Baron RL, Dodd GD III, Federle MP. Malignancies in patients with cirrhosis: CT sensitivity in 200 consecutive transplant patients. Radiology 1994;193:645-650
2. Dodd GD III, Miller WJ, Baron RL, Skolnick ML, Campbell WL. Detection of malignant tumors in end-stage cirrhotic livers: Efficacy of sonography as a screening technique. AJR 1992;159:727-733
3. Nelson RC, Chezmar JL, Sugarbaker PH, Bernadino ME. Hepatic tumors: Comparison of CT during arterial portography, delayed CT, and MR imaging for preoperative evaluation. Radiology 1989;171:47-51
4. Baron RL. Understanding and optimizing use of contrast material for CT of the liver. AJR 1994;163:323-331
5. Taourel PG, Pageaux GP, Coste V, et al. Small hepatocellular carcinoma in patients undergoing liver transplantation: detection with CT after injection of iodized oil. Radiology 1995;197:377-380
6. Manfredi R, Maresca G., Baron RL, et al. Gadobenate Dimeglumine [BOPTA] enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 1998;8:862-867
7. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium Benzyloxypropoinictetra-acetate (BOPTA)-Preliminary results of phase II clinical application. Radiology 1996;199:513-520
8. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: Evaluation with dynamic and static Gadobenate Dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 1997;205:721-728
9. Murakami T, Baron RL, Peterson MS, et al. Hepatocellular carcinoma: MR imaging with Mangafodipir Trisodium. Radiology 1996;200:69-77
10. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging - a multicenter phase III clinical study. Radiology 2000;215:727-736
11. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1999;33:798-809
12. Vittadini G, Felder E, Musu C, Tirone C. Preclincial profile of Gd-BOPTA; a liver specific MRI contrast agent. Invest Radiol 1990;5:559-560
13. De Haen C, Gozzini L. Soluble-type hepatobiliary contrast agents for MR imaging. J Magn Reson Imaging 1993;3:179-183
14. Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A. MultiHance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998;5(S):86-89
15. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerability, biodistribution and MR enhancement of the liver with Gd-BOPTA: results of clinical pharmacology and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 1999;6:282-291
16. Vogl TJ, Pegios W, McMahon C, Balzer J, et al. Gadobenate Dimeglumine-a new contrast agent for MR imaging: Preliminary evaluation in healthy volunteers. AJR 1992;158:887-892
17. Rosati G, Pirovano G, Spinazzi A. Interim results of phase II clinical testing of Gadobenate Dimeglumine. Invest Radiol 1994;29(S):183-185
18. Slater GJ, Saini S, Mayo-Smith W, Sharma P, et al. Mn-MPDP enhanced MR imaging of the liver: analysis of pulse sequence performance. Clin Radiol 1996;51:484-486
19. Peterson MS, Baron RL, Murakami T. Hepatic malignancies: usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging. Radiology 1996;201:337-345
20. Hamm B, Mahfouz AE, Taupitz M, et al. Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology 1997;202:677-682